EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism

Adrian F Daly iD, Albert Beckers iD

Endocrine Reviews · 2024

DOI: 10.1210/endrev/bnae014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, 2024. Verfasst von Adrian F Daly und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Domaine Universitaire Sart Tilman, 4000 Liège, Bel…. Hauptthemen laut MEDLINE: Gigantism, Genetic Diseases, X-Linked. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: Fonds d'Investissement Pour la Recherche Scientifique, Fonds d’Investissement Pour la Recherche Scientifique.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pituitary gigantism is a rare manifestation of chronic growth hormone (GH) excess that begins before closure of the growth plates. Nearly half of patients with pituitary gigantism have an identifiable genetic cause. X-linked acrogigantism (X-LAG; 10% of pituitary gigantism) typically begins during infancy and can lead to the tallest individuals described. In the 10 years since its discovery, about 40 patients have been identified. Patients with X-LAG usually develop mixed GH and prolactin macroadenomas with occasional hyperplasia that secrete copious amounts of GH, and frequently prolactin. Circulating GH-releasing hormone is also elevated in a proportion of patients. X-LAG is caused by constitutive or sporadic mosaic duplications at chromosome Xq26.3 that disrupt the normal chromatin architecture of a topologically associating domain (TAD) around the orphan G-protein–coupled receptor, GPR101. This leads to the formation of a neo-TAD in which GPR101 overexpression is driven by ectopic enhancers (“TADopathy”). X-LAG has been seen in 3 families due to transmission of the duplication from affected mothers to sons. GPR101 is a constitutively active receptor with an unknown natural ligand that signals via multiple G proteins and protein kinases A and C to promote GH/prolactin hypersecretion. Treatment of X-LAG is challenging due to the young patient population and resistance to somatostatin analogs; the GH receptor antagonist pegvisomant is often an effective option. GH, insulin-like growth factor 1, and prolactin hypersecretion and physical overgrowth can be controlled before definitive adult gigantism occurs, often at the cost of permanent hypopituitarism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GigantismGenetic Diseases, X-LinkedHumansReceptors, G-Protein-CoupledHuman Growth HormoneAcromegaly

Stichwörter der Autor:innen

GPR101X-linked acrogigantismfamilial isolated pituitary adenomagigantismtopologically associating domain

Substanzen

GPR101 protein, humanReceptors, G-Protein-CoupledHuman Growth Hormone

Autor:innen und Institutionen

  • Department of Endocrinology, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, Domaine Universitaire Sart Tilman, 4000 Liège, Belgium.

ORCID-Profile: Adrian F Daly, Albert Beckers

Förderung

  • Fonds d'Investissement Pour la Recherche Scientifique
  • Fonds d’Investissement Pour la Recherche Scientifique

Zitieren

APA

Daly, A. F., & Beckers, A. (2024). The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism. Endocrine Reviews. https://doi.org/10.1210/endrev/bnae014

Vancouver

Daly AF, Beckers A. The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism. Endocrine Reviews. 2024. doi:10.1210/endrev/bnae014

BibTeX
@article{Daly2024,
  author = {Daly, Adrian F and Beckers, Albert},
  title = {The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism},
  journal = {Endocrine Reviews},
  year = {2024},
  doi = {10.1210/endrev/bnae014}
}
Kostenlos starten →